No Overall Survival Benefit For Eisai’s Halaven In PhIII NSCLC Trial
This article was originally published in PharmAsia News
Prolongation of overall survival has not been achieved in an international Phase III trial with Eisai’s Halaven (eribulin mesylate) in the treatment of advanced non-small cell lung cancer.
You may also be interested in...
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”
With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.